We use cookies in order to analyze traffic of this website. Your further use of this website will be considered consent. For more information visit our Cookie Policy.

About us

Science

Pipeline

Media

Investors

Join us

Contact us

At AC Immune, we are passionate about making a difference in the lives of people affected by Alzheimer’s and other neurodegenerative diseases. Our goal is to become the global leader in precision medicine of neurodegenerative diseases that are one of the biggest challenges facing society today and future generations.

Latest news

December 15, 2021

AC Immune Awarded Two Michael J. Fox Foundation Grants to Advance Small Molecule Parkinson’s Disease Programs

November 12, 2021

AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response

November 10, 2021

AC Immune Announces Late-Breaker Presentation by Genentech at CTAD on Phase 2 Lauriet Study of Semorinemab in Mild-to-Moderate Alzheimer’s Disease

Features

December 20, 2021

Biotech Jahrbuch - Transkript.de
Alzheimer – neu im Lichtkegel

December 2, 2021

AC Immune – Im Kampf gegen Alzheimer und Parkinson
eine Interviewserie mit Dr. Matthias Hallweger

Company information

Discover more about us, who we are, and how we innovate to improve neurodegenerative disease understanding and develop breakthrough therapies.

Product pipeline

A broad pipeline focused on neurodegenerative diseases with complementary diagnostic agents driven by proprietary technology platforms.

Stock information

Up to date company stock information and analytics directly from Nasdaq